Recent News

• 03.26.2026 - Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
• 03.18.2026 - Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
• 11.13.2025 - Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
• 11.04.2025 - Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
• 10.21.2025 - PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
• 10.14.2025 - Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek
• 08.12.2025 - Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

Recent Filings

• 02.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.30.2026 - 8-K Current report
• 12.19.2025 - 8-K Current report
• 11.13.2025 - 8-K Current report
• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.12.2025 - 4 Statement of changes in beneficial ownership of securities